Loading...
•
Dec 31, 2020
Rockwell Medical Q4 2020 Earnings Report
Reported financial results and a business update.
Key Takeaways
Rockwell Medical reported Q4 2020 revenues of $15.2 million compared to $15.5 million for the same quarter of the previous year. Net loss was $8.7 million, or $(0.09) basic and diluted net loss per share, compared to a net loss of $7.3 million, or $(0.11) basic and diluted net loss per share, for the same period in 2019. The company ended the year with $58.7 million in cash, cash equivalents and investments.
Revenues were $15.2 million for the quarter ended December 31, 2020, compared to $15.5 million for the same period in 2019.
Triferic revenue was $0.5 million for the quarter ended December 31, 2020.
Net loss was $8.7 million, or $(0.09) basic and diluted net loss per share for the quarter ended December 31, 2020, compared to a net loss of $7.3 million, or $(0.11) basic and diluted net loss per share, for the same period in 2019.
Cash, cash equivalents, and investments available-for-sale totaled $58.7 million as of December 31, 2020.
Forward Guidance
Rockwell Medical is focused on the treatment of anemia in end-stage kidney disease and is working to expand the use of its FPC platform for the treatment of hospitalized patients with acute heart failure.
Positive Outlook
- The FDA has accepted Rockwell Medical's proposed development strategy to pursue an approval via the 505(b)(1) pathway as a novel new drug application (NDA) for FPC for treatment of iron deficiency anemia (IDA) in adult patients in the home infusion setting.
- Rockwell Medical plans to initiate a clinical study during the second half of 2021 for FPC for treatment of IDA in adult patients in the home infusion setting.
- Rockwell Medical is exploring the use of its FPC platform for the treatment of hospitalized patients with acute heart failure.
- Jeil filed a New Drug Application for Triferic (dialysate) and Triferic AVNU in Korea.
- Wanbang Biopharmaceuticals enrolled the first patient in a pivotal Phase 3 trial in China.
Challenges Ahead
- The company is facing challenges related to the COVID-19 pandemic, which is impacting its business and operating results.
- The company is subject to various risks and uncertainties, including those set forth in Rockwell Medical’s SEC filings.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...